1. Academic Validation
  2. Structural basis for pharmacological modulation of the TRPC6 channel

Structural basis for pharmacological modulation of the TRPC6 channel

  • Elife. 2020 Mar 9:9:e53311. doi: 10.7554/eLife.53311.
Yonghong Bai # 1 Xinchao Yu # 2 Hao Chen 3 Daniel Horne 4 Ryan White 4 Xiaosu Wu 5 Paul Lee 6 Yan Gu 3 Sudipa Ghimire-Rijal 1 Daniel C-H Lin 5 Xin Huang 1
Affiliations

Affiliations

  • 1 Department of Molecular Engineering, Amgen Research, Amgen Inc, Cambridge, United States.
  • 2 Department of Molecular Engineering, Amgen Research, Amgen Inc, South San Francisco, United States.
  • 3 Department of Protein Technologies, Amgen Research, Amgen Inc, Cambridge, United States.
  • 4 Department of Medicinal Chemistry, Amgen Research, Amgen Inc, Cambridge, United States.
  • 5 Department of Cardiometabolic Disorders, Amgen Research, Amgen Inc, South San Francisco, United States.
  • 6 Department of Discovery Technologies, Amgen Research, Amgen Inc, South San Francisco, United States.
  • # Contributed equally.
Abstract

Transient receptor potential canonical (TRPC) proteins form nonselective cation channels that play physiological roles in a wide variety of cells. Despite growing evidence supporting the therapeutic potential of TRPC6 inhibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 function and modulation remains obscure. Here we report cryo-EM structures of TRPC6 in both antagonist-bound and agonist-bound states. The structures reveal two novel recognition sites for the small-molecule modulators corroborated by mutagenesis data. The antagonist binds to a cytoplasm-facing pocket formed by S1-S4 and the TRP helix, whereas the agonist wedges at the subunit interface between S6 and the pore helix. Conformational changes upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation. Furthermore, structural and mutagenesis analyses suggest several disease-related mutations enhance channel activity by disrupting interfacial interactions. Our results provide principles of drug action that may facilitate future design of small molecules to ameliorate TRPC6-mediated diseases.

Keywords

Cryo-EM; drug discovery; human; molecular biophysics; structural biology.

Figures
Products